

Sudan, Republic of

Support for Vaccine: Meningococcal type A This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	ountry: Sudan, Republic of						
2.	Vaccine grant number:		16-SDN-08j-Y, 16-SDN-28a-X, 17-SDN-28a-X, 1820-SDN-28a-X					
3.	Date of Decision Letter: 30-Sep				30-Sep-19			
4.	Date of the F	the Partnership Framework Agreement: 10-Dec-13						
5.	Programme title: New Vaccine			Support (NVS), Meningococcal type A, Routine				
6.	Vaccine type: Meningoo		Meningococo	ccal type A				
7.	Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED							
8.	Programme	Duration:1	2016-2020					
9.	Programme Budget (indicative):2 (subject to the terms of the Partnership Framework Agreeme applicable)			greement, if				
		2016-2019	2020	2021	2022	2023	2024	Total ²
	Programme Budget (US\$)	3,291,890	630,000	-	-	-	_	3,921,890
10.	. Vaccine introduction grant							
		Approval						
		Year Grant M 2016 16-SDI Disburs Disbursement date						
						1,290,159		
		11 May	v, 2016		1,290,159			
11.	Product swit	tch grant						
	Not applicable							
12.	Indicative Annual Amounts: ³ (subject to the terms of the Partnership Framework Agreement, if applicable)			greement, if				
	Type of supplies to be							
	purchased with Gav							
		funds		2016-2019		2020		2021
	Number of v	vaccine doses				1,119,000		-

 $^{^{\}rm 1}$ This is the entire duration of the programme. $^{\rm 2}$ This is the total amount endorsed by Gavi for the entire duration of the programme. $^{\rm 3}$ This is the amount that Gavi has approved.



	Annual Amounts (US\$)	3,291,890	630,000	-
13.	Procurement agency:	UNICEF. The Country sha UNICEF.	Il release its co-financing payments each year to	0
14.	Self-procurement:	Not applicable		

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:

Accelerated transition nhaca

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	218,000	-	-	-	-
Number of AD syringes	167,700	-	-	-	-
Number of re-constitution syringes	24,000	_	-	-	-
Number of safety boxes	2,125	-	-	-	-
Value of vaccine doses (US\$)	118,133	-	1	-	-
Total co-financing payments (US\$) (including freight)	132,000	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

		Due dates
	or the annual procurement of vaccines, Country shall submit the ormation each year:	
•	vaccine stock levels including buffer stock, by end of March;	31 March 2020
•	number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.	15 May 2020
•	Countries shall report the actual switch date in the first renewal request following the actual implementation.	
	ce with applicable Gavi processes, Country shall report on ic and financial performance.	To be agreed with Gavi Secretariat



18.	Financial clarifications:	Country shall provide the following clarifications to Gavi*:
	Not applicable	
	* Failure to provide the financial clarificati	ons requested may result in Gavi withholding further disbursements.
19.	Other conditions:	
	Not applicable	

Signed by

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes

30 September 2019